Will CrowdStrike receive a DOJ/SEC enforcement action, Wells notice, or criminal charge related to the Carahsoft revenue recognition investigation by January 31, 2027?

The key update since the initial prediction is 3 additional months of silence. The investigation is now ~14 months old from when CrowdStrike first knew (Jan 2025) and ~9 months since public disclosure (June 2025). By resolution date (Jan 2027), it will be ~24 months from investigation start and ~19 months from disclosure. The Q4 FY2026 earnings call contained zero mentions of DOJ, SEC, investigation, Carahsoft, or related legal matters — management did not expand risk factor language, did not disclose a Wells notice, and did not announce a restatement. The securities class action was dismissed in January 2026. Three months of additional silence without any escalation signal — no Wells notice, no expanded disclosure, no DOJ press releases — is a modestly negative update for YES probability. SEC Wells notices typically come 18-30 months after investigation start, so the window is approaching but the silence pattern increasingly suggests the investigation may be winding down or deprioritized. However, scope expansion to HHS/DOE remains the strongest counter-signal. P(Wells by Jan 2027) ~15%, P(other formal action) ~4%, combined ~19%.

Evaluating the Bayesian update from the Q4 earnings silence. The prior was 0.23. Silence is genuinely ambiguous per the committee — 'cannot distinguish dying investigation from normal pace.' However, three distinct pieces of information shift downward: (1) No Wells notice after ~14 months from investigation start — while within the 18-30 month median window, the absence at 14 months is weakly informative; (2) Management chose not to expand risk factor disclosures, which public company counsel would push for if a Wells notice were imminent or received; (3) The class action dismissal removes one catalyst for SEC acceleration (parallel private litigation sometimes motivates SEC to move). Against these, the scope expansion (HHS/DOE) remains unresolved and suggests the investigation has substance. The restatement path remains low-probability (~3%) but independent of government timeline. Net assessment: modest downward revision from 0.23 to ~0.21.

Consider the tail risk scenarios carefully. The Carahsoft Contagion scenario (15-25% probability per committee) is the highest-impact path, but even if it materializes, the question asks whether formal enforcement action occurs BY January 2027 — not whether it ever occurs. Even in the contagion scenario, government procurement suspension requires a formal DOJ action that triggers FAR 9.407-1, which is extremely slow. The ARR Restatement Spiral (2-5% probability) could theoretically happen faster since it's company-initiated, but PwC has given clean audit opinions every year since IPO and a restatement would require PwC to reverse course — exceedingly rare without SEC pressure, which hasn't manifested. Criminal charges against C-suite (2-5% probability) are the slowest path of all — DOJ criminal investigations of this nature average 3-5 years. The 11-month silence since disclosure and 14-month investigation age, combined with no Wells notice and no expanded risk factors, pushes me to 0.20. The remaining 11 months to resolution is tight for any formal action to emerge.

The core question hasn't changed: this is a timing bet. Government investigations are slow. The 11-month silence since disclosure and zero mentions in Q4 earnings are modestly informative in favor of NO. The class action dismissal reduces external pressure. The investigation is now entering the Wells notice window (14 months from start), but no Wells notice has been issued. The remaining 11 months to resolution means we need a Wells notice or other formal action to emerge between now and Jan 2027 — possible but below base case. The restatement path is independently low-probability. The scope expansion to HHS/DOE is the strongest YES signal but also argues for a longer timeline (more complex case = more time). Net: ~0.20.

Strongest signal in this update: zero mention in Q4 FY2026 earnings call. Companies with imminent enforcement risk typically signal this through expanded risk factor language, litigation reserves, or at minimum careful language in prepared remarks. Complete silence from management, combined with complete silence from DOJ/SEC for 11 months, plus class action dismissal, paints a picture of an investigation that may be deprioritized or narrowing rather than expanding. The original scope expansion to HHS/DOE is concerning but that information is 8+ months old — if the expansion had yielded significant findings, we would likely see some signal by now. Insider selling remains 100% sell-side but this is typical for tech executives with large equity comp. I weight the absence of any escalation signal over 11 months more heavily than the 8-month-old scope expansion report.

Being cautious about over-updating on silence. Government investigations are supposed to be quiet — silence IS the base case for an active investigation, not evidence of it dying. The SEC regularly takes 2-3 years before issuing Wells notices, especially in complex multi-entity cases involving channel partner arrangements. The DOJ is even slower. The original 0.23 estimate already accounted for slow government timelines. The new information (3 more months of silence, no mention in Q4 earnings) is weakly informative at best — consistent with both active-and-building and dying investigation scenarios. The restatement path via PSU/ARR incentive nexus remains an independent risk channel. I resist a large downward revision: 0.22 is modestly lower than 0.23, reflecting a small update from the additional silence and class action dismissal, but acknowledging that silence is ambiguous.

11 months of silence, zero Q4 mentions, class action dismissed. Government investigations are slow. Resolution date is only 11 months away. Base rate for formal enforcement action within this remaining window is low. Previous estimate of 0.23 was reasonable at the time but additional silence warrants downward revision. Most likely outcome remains investigation ongoing with no formal action by Jan 2027.

Investigation is ~14 months old from start, entering Wells notice window. But 11 months of silence since disclosure and zero Q4 earnings mentions suggest no imminent action. Scope expansion to HHS/DOE indicates substance but also longer timeline. Wells notice remains most likely YES path at ~15% probability. Other paths (criminal charges, restatement) add ~3-5%. Combined ~20%.

No new positive signals for enforcement since initial prediction. Additional silence is modestly informative toward NO. Class action dismissal removes one catalyst. Zero earnings mentions suggest no imminent escalation. Previous 0.23 was right at the time; 3 months of quiet revises down to ~0.19. Main risk remains Wells notice in H2 2026 but probability is below base case.